Proceedings from the National Cancer Institute's second international workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: Part I: Biology of relapse after transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1537-1545

  Gress, Ronald E ^a   Miller, Jeffrey S ^b   Battiwalla, Minoo ^c   Bishop, Michael R ^d   Giralt, Sergio A ^e   Hardy, Nancy M ^a   Kröger, Nicolaus ^f   Wayne, Alan S ^a,g   Landau, Dan A ^h   Wu, Catherine J ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Biology; Prevention; Relapse; Stem cell transplantation; Treatment

Indexed keywords

KERATINOCYTE GROWTH FACTOR; SOMATOMEDIN C; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER RECURRENCE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; EPITHELIUM CELL; GENETIC HETEROGENEITY; GENOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENCE; LONGITUDINAL STUDY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MYELOABLATIVE CONDITIONING; NATIONAL HEALTH ORGANIZATION; NATURAL KILLER CELL; OUTPATIENT CARE; REDUCED INTENSITY CONDITIONING; RELAPSE; THERAPY EFFECT; TUMOR MICROENVIRONMENT; WORKSHOP;

ALLOGENEIC; BIOLOGY; PREVENTION; RELAPSE; STEM CELL TRANSPLANTATION; TREATMENT;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES;

EID: 84885764454     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.08.010     Document Type: Article

References (48)

1. Boyiadzis M., Memon S., Carson J., et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant 2008, 14:290-300.
2. Fagnoni F.F., Oliviero B., Giorgiani G., et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004, 104:281-289.
3. Peggs K.S., Verfuerth S., Pizzey A., et al. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 2003, 9:198-205.
4. Hakim F.T., Memon S.A., Cepeda R., et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. JClin Invest 2005, 115:930-939.
5. Mackall C.L., Bare C.V., Granger L.A., et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. JImmunol 1996, 156:4609-4616.
6. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. NEngl J Med 1995, 332:143-149.
7. Mackall C.L., Fleisher T.A., Brown M.R., et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997, 89:3700-3707.
8. Mackall C.L., Fleisher T.A., Brown M.R., et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
9. Mackall C.L., Gress R.E. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997, 157:61-72.
10. Hakim F.T., Cepeda R., Kaimei S., et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997, 90:3789-3798.
11. Matsuoka K., Kim H.T., McDonough S., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. JClin Invest 2010, 120:1479-1493.
12. McIver Z., Melenhorst J.J., Wu C., et al. Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. Haematologica 2012, 98:346-352.
13. Beyer M., Schumak B., Weihrauch M.R., et al. Invivo expansion of naive CD4+ CD25 (high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One 2012, 7:e30422.
14. Koreth J., Matsuoka K., Kim H.T., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEngl J Med 2011, 365:2055-2066.
15. Gattinoni L., Lugli E., Ji Y., et al. Ahuman memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
16. Brentjens R.J., Curran K.J. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Progr 2012, 2012:143-151.
17. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. NEngl J Med 2012, 366:2443-2454.
18. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants [comment]. Science 2002, 295:2097-2100.
19. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
20. Venstrom J.M., Pittari G., Gooley T.A., et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. NEngl J Med 2012, 367:805-816.
21. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
22. Winter C.C., Gumperz J.E., Parham P., et al. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. JImmunol 1998, 161:571-577.
23. Arase H., Mocarski E.S., Campbell A.E., et al. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002, 296:1323-1326.
24. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
25. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.
26. Foley B., Cooley S., Verneris M.R., et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood 2011, 118:2784-2792.
27. Foley B., Cooley S., Verneris M.R., et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012, 119:2665-2674.
28. Burns L.J., Weisdorf D.J., DeFor T.E., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32:177-186.
29. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
30. Geller M.A., Cooley S., Judson P.L., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
31. Bachanova V., Burns L.J., McKenna D.H., et al. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010, 59:1739-1744.
32. Gleason M.K., Verneris M.R., Todhunter D.A., et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 2012, 11:2674-2684.
33. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
34. Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. NEngl J Med 2011, 365:2497-2506.
35. Campbell P., Pleasance E., Stephens P., et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 2008, 105:13081-13086.
36. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
37. Egan J.B., Shi C.X., Tembe W., et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120:1060-1066.
38. Snuderl M., Fazlollahi L., Le L.P., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20:810-817.
39. Ene C.I., Fine H.A. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 2011, 20:695-697.
40. Oravecz-Wilson K.I., Philips S.T., Yilmaz O.H., et al. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell 2009, 16:137-148.
41. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
42. Mullighan C.G., Phillips L.A., Su X., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
43. Maley C.C., Galipeau P.C., Finley J.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006, 38:468-473.
44. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
45. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12:335-348.
46. Landau D.A., Stojanov P., Lawrence M.S., et al. Shifts in intra-clonal dynamics rather than novel mutations are the main engine driving tumor evolution in relapsed CLL. Blood 2011, 118:131-132.
47. Gatenby R.A., Silva A.S., Gillies R.J., Frieden B.R. Adaptive therapy. Cancer Res 2009, 69:4894-4903.
48. Dreger P., Dohner H., Ritgen M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116:2438-2447.